# Screening for distress: what the thermometer can and cannot do

Source: https://onco.cc/technologies/rejuv-mind-distress-screening/  
OnCo record `rejuv-mind-distress-screening` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The one-question distress thermometer is good at ruling depression out and poor at ruling it in: pooled across 38 analyses of 6,414 patients, sensitivity 78.4 per cent, specificity 66.8 per cent, and only 34.2 per cent who screened positive were depressed. Tested as a way of improving outcomes rather than finding cases, the one randomised trial found no improvement.

## Summary

Ultra-short screening, meaning fewer than five questions, became standard in cancer services because it is quick and because guidelines asked for it. A meta-analysis pooled 38 diagnostic validity analyses in cancer settings, 19 of them of the distress thermometer alone, covering 6,414 unique patients. For depression the pooled sensitivity was 78.4 per cent, specificity 66.8 per cent, positive predictive value 34.2 per cent and negative predictive value 93.4 per cent. The authors' summary is exact: "these tools were very good at excluding possible cases of depression but poor at confirming a suspected diagnosis". For anxiety, sensitivity 77.3 per cent and specificity 56.6 per cent; for distress in general, sensitivity 78.3 per cent and specificity 66.5 per cent. Results for the thermometer alone were similar. Their conclusion: "Ultra-short methods cannot be used alone to diagnose depression, anxiety, or distress in cancer patients but they may be considered as a first-stage screen to rule out cases of depression."

What that means in a clinic. A score below the cut-off is informative: it makes depression unlikely. A score above it is a reason for a conversation, not a diagnosis, and roughly two in three people who cross it do not have the condition. A service that screens and then treats the score rather than the person will treat the wrong people.

The harder finding is about screening as an intervention. A systematic review searched for randomised trials of two different things: treating distress in patients identified as distressed, and the effect of screening itself on distress outcomes. It found 14 eligible randomised trials of treatment, which "generally reduced distress with small to moderate effects", and exactly one randomised trial of the effect of screening on psychological outcomes, which "found no improvement". The reviewers concluded: "Because of the lack of evidence of beneficial effects of screening cancer patients for distress, it is premature to recommend or mandate implementation of routine screening."

That review was published in 2013 and its search closed in 2012, so it is a statement about the evidence at that time rather than a final verdict, and screening has since been written into accreditation standards in several countries. The point that survives is structural and is not controversial: screening can only help if what follows it is a service. Finding distress and having nowhere to send it changes nothing, and the one trial that measured the effect of finding it is consistent with that.

How this connects to the rest of this front. The distress thermometer asks about the last week on a 0 to 10 scale with an accompanying problem list covering practical, family, emotional, spiritual and physical problems, so it is a reasonable way to open a conversation about money, work, a carer or sleep, all of which have records here, and a poor way to decide who needs a psychiatrist. The ASCO 2023 guideline's stepped-care model is the structure that makes a positive screen useful: education for everyone, named psychological therapies for moderate symptoms, more intensive therapy for severe ones, and medication placed after those rather than before them.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:moderate; psychosocial
- Principle: A screening test's usefulness depends on the prevalence of what it is looking for. With major depression at roughly one in six in cancer settings, a test with 78 per cent sensitivity and 67 per cent specificity will flag far more people without the condition than with it, which is arithmetic rather than a flaw in the instrument. Ultra-short tools are therefore properly used as the first stage of a two-stage process, where a positive result triggers a structured assessment rather than a treatment decision.
- Strengths: Pooled diagnostic accuracy from 38 analyses and 6,414 patients, not a single validation study; A negative predictive value of 93.4 per cent makes a low score genuinely reassuring; The problem list opens conversations about money, work and carers that otherwise do not happen
- Limitations: Only about one in three positive screens is a case of depression; The single randomised trial of screening as an intervention found no improvement in distress; A screen without a service behind it changes nothing

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Psycho-oncology
- Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders (JCO 2007): https://doi.org/10.1200/JCO.2006.10.0438
- Effects of screening for psychological distress on patient outcomes in cancer: a systematic review (J Psychosom Res 2013): https://doi.org/10.1016/j.jpsychores.2013.01.012
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (JCO 2023): https://doi.org/10.1200/JCO.23.00293

## Connected records

- ideas: [Screen every cancer patient for financial toxicity as a vital sign, with navigation](https://onco.cc/ideas/idea-reg-financial-toxicity-vital-sign/), [Screen every patient for financial hardship at diagnosis and connect them to help](https://onco.cc/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Anxiety after cancer, in survivors and in their partners](https://onco.cc/technologies/rejuv-mind-anxiety-after-cancer/), [Depression during and after cancer: the interview-based prevalence, and the care model that works](https://onco.cc/technologies/rejuv-mind-depression-after-cancer/), [Fear that the cancer will come back: how common it is, and when it stops being ordinary worry](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence/), [Financial toxicity and financial navigation](https://onco.cc/technologies/financial-navigation/), [Getting psychological help after cancer: the stepped-care model, and what is actually commissioned](https://onco.cc/technologies/rejuv-mind-access-to-psychological-care/), [Measuring fear of recurrence: the FCRI and its cut-off](https://onco.cc/technologies/rejuv-measure-fear-of-recurrence-inventory/), [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [PROMIS: the item banks that let a short questionnaire be precise](https://onco.cc/technologies/rejuv-measure-promis/), [Psycho-oncology and distress screening](https://onco.cc/technologies/psycho-oncology/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/)
- terms: [Quality of life](https://onco.cc/terms/quality-of-life/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-mind-distress-screening.json